NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Variant Bio

Variant Bio

Private
Seattle, WashingtonHealthcare & Life Scienceshttps://www.variantbio.com/

Last Round

Series B

Nov 1, 2021

Est. Valuation

$225M

Total Funding Raised

$122.5M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Variant Bio is a biotechnology company that develops life-saving therapies by studying the genes of people with exceptional health-related traits.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Medical AI, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Usage-Based SaaS

AI Layer

Application

Keywords

drug discoveryAI drug discoverygenomic drug discoverytarget identificationagentic AIbiotech AIhuman genomicskidney diseasemetabolic diseaseprecision medicinemulti-omicsstatistical geneticsin silico discoverypharma R&DAI-native biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Variant Bio Comparables

Compare Variant Bio with similar companies based on industry and business-model similarity.

Variant Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
BenevolentAI
81%
Verge Labs
80%
Xaira Therapeutics
78%

Variant Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BNov 1, 2021
Series AMay 28, 2020
SeedOct 1, 2018

Key People

Founding team and executive leadership

Stephane Castel

Co-Founder, Chief Technology Officer

Founding Team

Holly Vance

Chief Operating Officer Chief Legal Officer

Executive Team

Variant Bio Investors

Notable investors and investment history

Variant Bio investors
InvestorRounds
SoftBank Investment AdvisersSeries B
Vulcan CapitalSeries B
SoftBank GroupSeries B
Lux CapitalSeries B, Seed, Series A
Biomatics Capital PartnersSeries A
Venture HighwaySeries B
Cercano ManagementSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 21, 2026

    Craig T. Basson appointed Chief Medical Officer and President of R&D.

  • Jan 6, 2026

    Partnered with Boehringer Ingelheim to discover novel drug targets for kidney disease.

Variant Bio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Variant Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Variant Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersSeattle, Washington
Employee Range37
Year Founded2018
Last FundingNov 1, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.